The alpha thalassemia market is expected to expand significantly through 2036, driven by rising prevalence and advancements in diagnostics and gene therapies. Key players Agios Pharmaceuticals and Novo Nordisk are leading development efforts with emerging drugs like PYRUKYND and etavopivat progressing through clinical trials, though no gene therapies are currently approved for the condition.

Agios Pharmaceuticals announced it will host a conference call on April 29, 2026, to report Q1 2026 financial results. The company is advancing mitapivat toward potential U.S. accelerated approval in sickle cell disease following a pre-sNDA meeting with the FDA, and has received approval for PYRUKYND (mitapivat) for adults with thalassemia in the United Arab Emirates.

Agios Pharmaceuticals stock surged over 21% after the FDA approved an accelerated approval pathway for its mitapivat drug to treat sickle cell disease. The company can now conduct an abbreviated confirmatory trial before seeking full FDA approval within months. While the drug shows promise in a market expected to grow from $4B to $14B by 2034, investors should note Agios remains unprofitable with significant losses despite recent gains.

Viswanadhan Krishnan, Chief Corporate Development and Strategy Officer at Agios Pharmaceuticals, sold 2,959 shares worth ~$82,000 on March 5, 2026. However, this was a routine, pre-planned tax-withholding sale triggered by RSU vesting, not a discretionary sale indicating loss of confidence. Krishnan retains 16,200 unvested RSUs and recently received fresh compensation grants, signaling growing equity stake. Agios' lead drug PYRUKYND showed strong 86% revenue growth, and the company announced plans to pursue FDA accelerated approval for sickle cell disease.

Agios Pharmaceuticals announced it will host a conference call and live webcast on February 12, 2026, at 8:00 a.m. ET to report its fourth quarter and full year 2025 financial results and business highlights. The company also outlined its 2026 strategic priorities and key milestones to accelerate rare disease portfolio growth.

Agios Pharmaceuticals shares surged over 18% following FDA approval of AQVESME (mitapivat) for treating alpha- and beta-thalassemia. The company priced the drug at $425,000 annually in the U.S. and projects $1 billion in global peak-year sales across thalassemia and pyruvate kinase deficiency indications. Management's positive conference call and expansion plans drove investor enthusiasm.

The FDA has approved Agios Pharmaceuticals' AQVESME (mitapivat), an oral pyruvate kinase activator, for treating anemia in adults with alpha- or beta-thalassemia. AQVESME is the only FDA-approved medicine for both non-transfusion-dependent and transfusion-dependent forms of the disease. The approval is based on Phase 3 ENERGIZE and ENERGIZE-T trials showing significant improvements in hemoglobin levels, fatigue, and transfusion burden. The drug will be available in late January 2026 under a REMS program due to hepatocellular injury risks observed in clinical trials.

The sickle cell disease market is projected to grow at a 22.1% CAGR by 2034, driven by increasing disease prevalence, awareness, and advancements in gene therapies, with emerging treatments from multiple pharmaceutical companies.

Agios Pharmaceuticals' stock dropped nearly 50% after mixed Phase 3 trial results for its sickle cell disease drug mitapavit. The drug met one primary endpoint of hemoglobin response but failed to significantly reduce sickle cell pain crises.

Agios Pharmaceuticals received a positive opinion from the European Medicines Agency for PYRUKYND, a treatment for thalassemia in adults. The drug shows promise in treating anemia associated with alpha- and beta-thalassemia, with a final European Commission decision expected in early 2026.

Agios Pharmaceuticals will host a Q3 2025 financial results conference call on October 30, and announced an FDA PDUFA goal date extension for PYRUKYND in thalassemia treatment. The company also received approval for PYRUKYND in Saudi Arabia.

The thalassemia treatment market is expected to grow significantly by 2034, driven by novel drug developments, emerging therapies like pyruvate kinase activators, and improved diagnostic technologies. Currently, no approved drugs exist for alpha thalassemia, but several treatments are available for beta thalassemia.